Brazil: from universal ARV access to universal HCV treatment? Juliana Vallini Friday, 23rd, July, 2010.

Slides:

Advertisements

Similar presentations

The WTO TRIPS Agreement, Innovation and Access to Medicines Does the emperor have any clothes at all? HAI Europe 25th Anniversary Conference, Oct 26 -

Advertisements

The Brazilian Response to AIDS Mauro Teixeira de Figueiredo Head of the Division for Technical Cooperation International Advisory Ministry of Health Main.

UN-OHRLLS International support measures and financial resources for LLDCs Gladys Mutangadura UN-OHRLLS.

HIV/AIDS in Brazil at a glance 11th Advanced HIV Course 1 – 3 September 2013, Aix-en-Provence, France Ana Flor Hexel Cornely Clinical Hospital, Porto Alegre.

WHO/WIPO/WTO Meeting Geneva, July 2010 Procurement and Supply Management Approach Monitoring Availability and Pricing WHO/WIPO/WTO technical Symposium.

Ellen t Hoen, MSF Høsbjør, 8-11April 2001, WHO-WTO Workshop Differential Pricing 1 WHO-WTO Workshop Differential Pricing and Financing of Essential Drugs.

The Medicines Patent Pool Increasing Access, Stimulating Innovation Ellen t Hoen Medicines Patent Pool Consultative Expert Group on R&D Financing and Coordination.

PROCURING AND DISTRIBUTING ARVs AND OTHER A.R.T COMMODITIES IN MALAWI Technical Briefing for Consultants in Procurement and Supply Management for HIV,

1 Brazilian Governments move to promote Broadband access throughout the country Cristina Coutinho Moreira 8 September 2008, ITU Headquarters, Geneva, Switzerland.

DEVELOPING COUNTRIES AND IP: ACCESS TO HEALTH CARE EDUCATION MATERIALS Karen A. LeCuyer, Ph.D. University of Connecticut School of Law 30 May 2007.

2 ND WIPO INTER-REGIONAL MEETING ON SOUTH-SOUTH COOPERATION ON PATENTS, TRADEMARKS, GEOGRAPHICAL INDICATIONS, INDUSTRIAL DESIGNS AND ENFORCEMENT CAIRO.

Gilead’s Tech Transfer Partnerships and IP in India

Working world wide against HIV for the health and human rights of men who have sex with men Working world wide against HIV for the health and human rights.

UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ROMANIAN DEVELOPMENT CAMP Second.

Fostering R&D and Promoting Access to Medicines (for all) From Alma Ata, via Doha to Geneva (in 10 minutes) Bellagio, Italy October 2007 Ellen ‘t.

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.

Francisco Viegas Neves da Silva ¹ ; Ronaldo Hallal² and André Guimarães ² International Cooperation Unit ¹ Care and Quality of Life Unit ² Department of.

Ani Shakarishvili, MD UNAIDS Country Coordinator in Ukraine AIDS 2012, Washington, DC – 23 July, 2012 Ensuring the financial sustainability of the national.

Ensuring generic competition for effective price reduction in Ukraine Olga Stefanyshyna Executive director CF «Patients of Ukraine» 24 th of July 2014.

Options for national or regional production or procurement Wilbert Bannenberg SARPAM.

Innovation and Access to Medicines: A Case Study for HIV/AIDS and Hepatitis C Dr Manica Balasegaram, WIPO Seminar, 2014.

Panorama of the pharmaceutical patenting and sanitary registration of ARVs drugs in Brazil: implications to access and to health industrial complex Pedro.

Patent Pools Increasing access to Medicines and Innovation Ellen ‘t Hoen MSF Access to Essential Medicines Campaign Barcelona 9 Dec

Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.

Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

Opportunities & Challenges: Expanding Access to Hepatitis C Treatment Gregg Alton Executive Vice President, Corporate & Medical Affairs.

The use of TRIPS flexibilities to protect health in South Africa and the opportunities for pro-public health reform of national legislation Nokhwezi Hoboyi.

IGWG process Gaudenz Silberschmidt, Switzerland Public Health, Innovation and Intellectual Property Global strategy and Plan of Action Dr Gaudenz Silberschmidt,

Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

Implementation of TRIPS Flexibilities In National IP Legislation For Strengthening Access To Medicines In Swaziland Workshop with MOH and stakeholders,

A very short introduction to patents & access to medicines.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.

Public health, innovation and intellectual property 1 |1 | Dr Germán Velásquez Director WHO Secretariat Public Health, Innovation and Intellectual Property.

Access to medicines, WTO TRIPS and Seychelles patent law Ellen ‘t Hoen, Medicines Law & Policy Seychelles September 2014.

Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Zambia TRIPS workshop 3 Oct 2013.

PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.

Action against AIDS, Germany: Dr. Christiane Fischer MD PHD (presenter )(BUKO Pharma-Kampagne), Astrid Berner Rodoreda (Bread for the World) Igor Oliynyk.

Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?

Impacts of TRIPS on access to care The post-2005 issues Benjamin CORIAT University Paris 13 and ANRS ANRS – MoH Brazil Satellite Meeting Mexico, August.

ARV Drugs : Brazilian Innovation System and the Importance for BRICS Countries José Eduardo Cassiolato Luiz Antônio Elias Graziela Ferrero Zucoloto.

Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.

Hu Yuanqiong China Access to Medicines Research Group OSF Seminar Bangkok; Access to Medicines and IPR Advocacy in China -- Review and initial.

Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.

AIDS Medicines and Diagnostics Services - a network of organizations supporting access to HIV medicines and diagnostics J. Perriëns.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Ellen ‘t Hoen Médecins sans Frontières

Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.

Tensions between Brazil and the United States

Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.

Universal Access: To what extent current mechanisms are appropriate and sustainable to maintain free of charge treatment? Compulsory Licensing in Brazil.

Access to ARVs in Brazil: challenges for civil society XVII International Aids Conference Satellite Meeting on Access to Medicines and Intellectual Property.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.

MSF Access to Essential Medicines Campaign

How Pricing Affects Availability

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

How Advocacy can Influence Pricing & Policy

PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES

Drug Pricing Policies and Challenges

Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.

Presentation transcript:

Brazil: from universal ARV access to universal HCV treatment? Juliana Vallini Friday, 23rd, July, 2010

Brazilian Context Health system with universal access to the population; Fundamental human right; Integrated programs of Viral Hepatitis and AIDS.

Brazilian Context – Hepatitis patients. Total expenditure: -Pegylated interferon: R$ , – 2010 R$ ,00. - Interferon: R$ 1.562, R$ ,00. (rate: US$1= BR$1,79). Merck x Roche.

Brazilian Context Lowering ARV prices in Brazil: - Use of TRIPS flexibilities. - Not granting frivolous patents (TDF case as an example). - Information about the product.

Post- grant aspects and price negotiation. Prices in other developing countries (MIC) Regulatory aspects (If there is a generic registered) Local production or importation (south-south cooperation for R&D) Quantity

Tenofovir 1 st line ARV – increase fastly - 47,000 patients (2009) Patent deposited in Brazil in1995 Opposition MoH declared it of public interest in April 2008 Brazilian Patent Office does not grant the patent (2009) HIV/AIDS and hepatitis B. - Brazil – price reduction US$ 47 mi. - Adefovir (GSK) x Tenofovir (Gilead) CIPLA- prequalified Not granted in India too.

2009 TDF = US$ 42 millions = 14,7% budget imported ARV

Challenges Expand access to fair prices to HV medicines. Use of the TRIPS flexibilities as reiterated by the Doha Declaration on TRIPS and Public Health and in the last WHA resolution related to VH. WHA 2008 – Global Strategy on Innovation, Public Health and Intellectual Property – put it into practice – VH is included. The need for cooperation and exchange of information among the developing countries (south- south). Transfer of technology.

Thank you!